ALLO Allogene Therapeutics
- 3.070
- +0.100+3.37%
- 3.170
- +0.100+3.26%
Allogene Therapeutics News
Allogene Therapeutics | EFFECT: Others
Allogene Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer MOORE TIMOTHY L.
Allogene Therapeutics | ARS: Annual Report to Security Holders
Allogene Therapeutics | DEFA14A: Others
Allogene Therapeutics | DEF 14A: Definitive information statements
Allogene Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Allogene Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Chang David D
Allogene Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Allogene Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Allogene Therapeutics | 10-K: Annual report
Allogene Therapeutics | POSASR: Post-effective amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR
Allogene Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Allogene Therapeutics | 8-K: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Allogene Therapeutics | 10-K/A: Annual report (Amendment)
Allogene Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Parker Geoffrey M.
Allogene Therapeutics | UPLOAD: Others
Allogene Therapeutics | CORRESP: CORRESP
Allogene Therapeutics | 8-K: Current report
Allogene Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Arie Belldegrun, M.D.(5.8%),Bellco Legacy IV, LLC(2.8%), etc.
Allogene Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-David Chang, M.D., Ph.D.(5.8%),Chang 2006 Family Trust(0.7%), etc.
Analysis
Price Target
No Data
